Pay in 4 interest-free payments of $5.41 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Walk in during open hours and our team will take care of you
Here are some key findings: Within six months of starting GLP-1 therapy, the rate of hypotensive events increased from 8.7% to 10.2% The increased risk remained significant at 12 months, with hypotensive events rising from 13.6% to 14.3% Adults age 65 and older accounted for 53% of hypotensive events despite representing 37% of the study population Patients with Type 2 diabetes made up 75% of those experiencing hypotensive episodes but only 63% of the overall cohort In secondary analyses, the scientists found that weight loss alone did not explain the increased risk, suggesting other mechanisms of action may be at play Northwestern Now posed five questions to the study senior author Dr
352 Intravitreal injection of anti-VEGF agents has provided an effective alternative to panretinal laser photocoagulation therapy for PDR
If you would like to cancel your order, please get in touch with our Patient Support team immediately
